Are you interested in adding some more ASX shares to your portfolio?
Five ASX shares that could be worth considering this month are listed below. Here's what you need to know about them:
CSL Limited (ASX: CSL)
CSL is the biopharmaceutical giant behind the CSL Behring and Seqirus businesses. These two businesses have a host of lucrative therapies and vaccines that generate billions in revenue each year. CSL also invests significantly in its research and development pipeline and will be putting almost US$1 billion into these activities in FY 2021. By doing this, it ensures that the company stays ahead of the curve and has a pipeline of potentially life-saving products. One of those is Clazakizumab, which is being developed to treat kidney transplant rejection. This product alone has the potential to generate peak sales of US$5.4 billion if successful. Citi recently upgraded its shares to a buy rating with a $310 price targe
Domino's Pizza Enterprises Ltd (ASX: DMP)
This pizza chain operator could be worth considering due to its strong market position and bold growth targets over the next decade. At the last count, Domino's had a network of 2,800 stores. However, it is aiming to grow this organically to 5,500 stores by 2033. Management is also looking for possible acquisitions, which would increase its footprint even further. Combined with its same store sales growth target and operating leverage, Domino's looks well-placed to deliver strong earnings growth over the 2020s. Goldman Sachs is very positive on the company. It recently put a buy rating and $112.60 price target on its shares.
Nanosonics Ltd (ASX: NAN)
Nanosonics is one of the world's leading infection prevention companies. It is the name behind the trophon EPR disinfection system for ultrasound probes. This product is regarded as the best in its class and has been capturing market share consistently over the last decade. This has underpinned strong unit sales and even stronger recurring revenues from the consumables that the system requires. Looking ahead, the increased importance of infection prevention following the pandemic and potential new product launches look set to underpin strong growth over the long term. UBS is positive on Nanosonics and currently has a buy rating and $7.00 price target.
Nearmap Ltd (ASX: NEA)
Nearmap is a leading aerial imagery technology and location data company with operations in the ANZ and North American markets. It provides businesses with instant access to high resolution aerial imagery, city-scale 3D datasets, and integrated geospatial tools. While its growth has been a bit up and down over the last couple of years, management appears confident on the future. It is targeting annualised contract value (ACV) growth of 20% to 40% per annum over the long term. Underpinning this growth will be the release of its next generation of the world's leading aerial camera system – HyperCamera3, and its artificial intelligence offering. Goldman Sachs recently put a buy rating and $2.95 price target on Nearmap's shares.
NEXTDC Ltd (ASX: NXT)
NEXTDC is a leading data centre operator. It has been benefiting greatly in recent years from the increasing amount of data being generated by consumers and businesses. This has certainly been the case during the pandemic thanks to the accelerating shift to the cloud. This led to a surge in demand for data centre capacity. In fact, NEXTDC even has a significant amount of its future capacity already contracted. This bodes well for its future growth, as does its potential expansion into Singapore and Tokyo in the near future. UBS is a fan of the company and has a buy rating and $15.40 price target on its shares.
